BioCryst Pharmaceuticals (BCRX) reported its Q4 swung to earnings Thursday of $1.12 per diluted share, compared with a loss of $0.13 a year earlier.
Analysts polled by FactSet expected $0.06.
Revenue for the quarter ended Dec. 31 was $406.6 million, up from $131.5 million a year earlier.
Analysts polled by FactSet expected $151.9 million.
For full-year 2026, BioCryst maintained its guidance for total revenue of $635 million to $660 million.
Analysts polled by FactSet expected $657.1 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments